French investigator and clinician Pierre Miossec, MD, PhD, will deliver the keynote address of the Basic & Clinical Research Conference, tracing the discovery of IL-17 almost 30 years ago and reviewing how this key cytokine affects skin joint targets and the link between cardiovascular disease…

One of the key questions for this therapy is the durability of CAR-T response in autoimmune diseases, which Anca Askanase, MD, MPH, and George Tsokos, MD, will discuss in a session on the history and future of cellular therapy in rheumatic diseases.

Timely communication of evolving safety information is a critical element in providing the best care for patients. Representatives from the U.S. Food and Drug Administration, including Amit Golding, MD, PhD, will give an update on safety issues in the treatment of rheumatic diseases.

Artificial intelligence (AI) is not going to replace rheumatologists now or in the foreseeable future; however, using AI to help patients, improve clinic workflows, and facilitate research is forthcoming, says Bella Mehta, MD. Multiple sessions at ACR Convergence will highlight the potential of this technology.

Work-life balance is a prominent topic this year because of its potential to shape careers, explained Roneka Ravenell, MD, Chair of the Business of Rheumatology Team for the Annual Meeting Planning Committee, who previewed high-interest sessions for ACR Convergence Today.

These sessions are targeted to anyone actively involved in maintaining, recruiting, and sustaining the rheumatology workforce. Lisa Zickuhr, MD, MHPE, Chair of the Education and Workforce Team for the Annual Meeting Planning Committee, provides an overview of what to expect.

Explore the Exhibit Hall Saturday–Monday and discover medical advancements that are sure to change patient care and biosimilars, as well as other clinical trial developments that are likely to have a significant impact on the practice of rheumatology.